InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,188.00
(
0.74%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.58
(
-0.04%
)
Bitcoin
59,103.90
(
-0.42%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2622
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: 10nisman post# 111373

Thursday, 12/23/2010 12:04:31 PM

Thursday, December 23, 2010 12:04:31 PM

Post# of 252864

This response supports Teva's belief that even slight changes to a glatiramoid like Copaxone® can significantly and unpredictably influence the efficacy, toxicity and immunogenicity profile of the compound.



Ya gotta love their "spin" capacity.

This looks good for MNTA for two reasons. There will not be an alternative-C diluting the C-market. FDA's sensitivity to "sameness" plays to the MNTA advantage.

ij

There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up